

Anti-Beta-galactosidase [13R4] Standard Size Ab00135-10.2

This antibody has a mutation to remove the CH2 IgG glycosylation site.

This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls.

Isotype and Format: Human IgG1, Aglycosylated, Lambda

Clone Number: 13R4

Alternative Name(s) of Target: beta-gal; Acid beta galactosidase; Beta galactosidase 1; β -galactosidase; β -gal; EBP; ELNR1; Galactosidase beta 1; GLB1; MPS4B

UniProt Accession Number of Target Protein: P00722

Published Application(s): negative control, WB, FC

Published Species Reactivity: E. coli

Immunogen: Beta-galactosidase.

Specificity: 13R4 recognizes wild-type E. coli beta-galactosidase.

Application Notes:

Antibody First Published in: Martineau P, Jones P, Winter G. Expression of an antibody fragment at high levels in the bacterial cytoplasm. J Mol Biol. 1998 Jul 3;280(1):117-27. [PMID:9653035](#)

Note on publication: Describes the parent scFv13 antibody improved by four rounds of random mutagenesis leading to optimised scFv13R4; scFv13R4 was selected for its capacity to fold correctly in a reducing environment such as the cytoplasm.

Product Form

Size: 200 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.